Lupin launches generic epilepsy drug

BALTIMORE — The Food and Drug Administration has approved a generic drug for epilepsy made by Lupin Pharmaceuticals, the drug maker said.



Lupin announced the approval and launch of levetiracetam extended-release tablets in the 500-mg and 750-mg strengths.



The drug is a generic version of UCB's Keppra XR, which had sales of about $161 million during the 12-month period ended in June, according to IMS Health.